

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Consultees raised the issue of providing non-injectable medications for people with needle phobia.
--

Consultees raised the issue that low molecular heparins are derived from porcine heparin and some people may need to avoid them because of hypersensitivity, or for religious or cultural reasons.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

If the committee was not to recommend betrixaban, the guidance would apply equally to all patients. However, the committee would need to explore if there is a subgroup for which having no access to betrixaban is particularly unfair. At the workshop, clinicians commented that this does occur but is very uncommon. There will be locally available NHS guidance to help people requiring injections who have a phobia of needles.
--

The issue of needle phobia and animal-derived products will be brought to the committee's attention.
--

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director (name):Janet Robertson.....

Date: 03 November 2017